

AD-A065 947

OKLAHOMA UNIV HEALTH SCIENCES CENTER OKLAHOMA CITY D--ETC F/G 6/15  
A COMPARISON OF KETAMINE AND KETAMINE-XYLAZINE ANESTHESIA IN TH--ETC(U)  
FEB 79 G L WHITE, J F CUMMINGS N00014-76-C-0229  
TR-133 NL


UNCLASSIFIED

| OF |  
AD  
A095817



END  
DATE  
FILMED  
5-79  
DDC





MICROCOPY RESOLUTION TEST CHART  
NATIONAL BUREAU OF STANDARDS-1963-A

AD A0 659 47

**LEVEL II**

6

OFFICE OF NAVAL RESEARCH  
Contract N00014-76-C-0229  
Project No. NR 207-040

TECHNICAL REPORT NO. 133

A COMPARISON OF KETAMINE AND  
KETAMINE-XYLAZINE ANESTHESIA IN THE BABOON

Gary L. White and John F. Cummings

Prepared for Publication  
in  
Vet. Med./Small An. Clin.

DDC  
RECEIVED  
MAR 20 1979  
C

DDC FILE COPY

University of Oklahoma Health Sciences Center  
Department of Pathology  
Oklahoma City, Oklahoma

12 February 1979

Reproduction in whole or in part is permitted for  
any purpose of the United States Government

THIS DOCUMENT IS BEST QUALITY PRACTICABLE.  
THE COPY FURNISHED TO DDC CONTAINED A  
SIGNIFICANT NUMBER OF PAGES WHICH DO NOT  
REPRODUCE LEGIBLY.

This document has been approved  
for public release and sale; its  
distribution is unlimited.

79 03 16 028

## **DISCLAIMER NOTICE**

**THIS DOCUMENT IS BEST QUALITY PRACTICABLE. THE COPY FURNISHED TO DDC CONTAINED A SIGNIFICANT NUMBER OF PAGES WHICH DO NOT REPRODUCE LEGIBLY.**

6

OFFICE OF NAVAL RESEARCH

Contract <sup>15</sup> NO0014-76-C-0229

Project No. NR 207-040

<sup>9</sup> TECHNICAL REPORT, NO. 133

<sup>14</sup> TR-

<sup>8</sup> A COMPARISON OF KETAMINE AND  
KETAMINE-XYLAZINE ANESTHESIA IN THE BABOON

<sup>10</sup> Gary L. White and John F. Cummings

D D C  
RECEIVED  
MAR 20 1979  
R L B L I T L D  
C

Prepared for Publication

in

Vet. Med./Small An. Clin.

University of Oklahoma Health Sciences Center  
Department of Pathology  
Oklahoma City, Oklahoma

<sup>11</sup> 12 February 1979

<sup>12</sup> 14p.

Reproduction in whole or in part is permitted for  
any purpose of the United States Government

ACCESSION FOR		
NTIS	Other Section	<input checked="" type="checkbox"/>
DDC	8-4 Section	<input type="checkbox"/>
UNANNOUNCED		<input type="checkbox"/>
JUSTIFICATION		
BY		
DISTRIBUTION AVAILABILITY CODES		
Dist	AVAIL	SPECIAL
A	23 84	

411 106

vb

79 03 16 028



Ketamine HCl has gained wide acceptance in several species of animals, including non-human primates, as an anesthetic agent. It produces the dissociate state of anesthesia. Advantages of ketamine include intramuscular administration, rapid induction and safety.<sup>1,2</sup> Muscular hypertonicity and inadequate analgesia has been reported as undesirable characteristics of ketamine when used alone.<sup>3,4</sup> The combination of ketamine and xylazine has been found to increase analgesia and produces good muscle relaxation in several species.<sup>2,5,6</sup> The combination of ketamine and acepromazine in rhesus monkeys has been reported to eliminate muscular movement and produces satisfactory analgesia for short surgical procedures; however, the laryngeal reflexes were maintained thus preventing endotracheal intubation.<sup>7</sup>

The purpose of this study was to compare the induction time (interval between administration and peak effect), sleep time (interval from beginning of peak effect to first observed voluntary muscular movement), heart rate and muscle tone in baboons anesthetized with either ketamine alone or the combination ketamine-xylazine.

#### Materials and Methods

Six female baboons (Papio cynocephalus) weighing 14 to 15 kg were used in this study. Fecal cultures from each baboon were found to be negative for Salmonella and Shigella, and all baboons were negative on intrapalpebral tuberculin testing. All were also found to be negative for ova and parasites on fecal examination.

Group A baboons received 11 mg ketamine hydrochloride (Ketaset, Bristol Laboratories)/kg of body weight administered intramuscularly. Group B baboons received 11 mg ketamine hydrochloride and .5 mg xylazine (Rompum, Haver-Lockhart Laboratories)/kg of body weight administered intramuscularly given in a single injection. The same baboons were used in both groups with a two week interval

between each treatment. On the first day 3 baboons received ketamine alone and 3 received the combination of ketamine-xylazine. Then on the fifteenth day each group of 3 baboons was given the alternate treatment. The dosage of ketamine was chosen from a previous report for this species that utilized a mean dose of 11.3 mg/kg of ketamine.<sup>2</sup> The xylazine dosage was based on approximately half the dosage recommended by the manufacturer for dogs.

The induction time (interval between administration of drugs and peak effect) and sleep time (interval from the beginning of peak effect to first observed voluntary muscular movement) were measured as defined by a previous study in non-human primates.<sup>7</sup> Heart rate was measured with a Model 240 intensive care monitor (The Capston Company). Muscle relaxation and movement were subjective judgements.

The results were analyzed using t tests for paired and unpaired data.

### Results

Induction of anesthesia was smooth for both groups of baboons. Induction time for baboons receiving ketamine alone (Group A) ranged from 3 to 7 minutes (mean: 5.0 minutes; standard error of mean: 0.6 minutes; n=6) compared with a range of 2 to 5 minutes (mean: 4.0 minutes; standard error of mean: 0.5 minutes; n=6) for baboons receiving the ketamine-xylazine combination. Unpaired comparisons revealed no significant difference in induction time between the two groups. Sleep time for baboons administered ketamine alone ranged from 64 to 88 minutes (mean: 72.5 minutes; standard error of mean: 3.8 minutes; n=6) contrasted with a range of 90 to 125 minutes (mean: 106 minutes; standard error of mean: 4.7 minutes; n=6) for baboons injected with the ketamine-xylazine combination. The sleep time was prolonged significantly ( $p < 0.001$ ) in the ketamine-xylazine group when compared with the group administered ketamine alone.

Comparisons of heart rate between the two groups are presented in Table I. There were no significant changes in heart rate within the ketamine group from

10 minutes through 30 minutes; however, at +20 and +30 minutes the baboons administered the ketamine-xylazine had a significant decrease in heart rate when compared with the +10 minute rate. The ketamine-xylazine group of baboons had a lower ( $p < 0.02$ ) heart rate from +10 through +30 minutes when compared with the group receiving ketamine alone.

Several pertinent observations were made during this study. Group A baboons exhibited muscular hypertonicity contrasted with good muscle relaxation in the Group B baboons. Voluntary muscular movement was not observed in the baboons receiving the combination of ketamine-xylazine compared with some voluntary muscle movement of all 6 baboons anesthetized with ketamine alone. Muscle relaxation was sufficient in the Group B baboons to permit excellent ease of abdominal palpation and endotracheal tubes could be passed easily.

Blood gas measurements were not performed; however, no respiratory impairment was evident. All baboons were observed for 2 months with no untoward side effects being noted.

### Discussion

The combination of ketamine-xylazine has been shown to have advantages over ketamine alone in cats, rabbits and rats.<sup>2,5,6</sup> This study was conducted to compare the induction time, sleep time, heart rate and muscle tone in baboons anesthetized with either ketamine alone or the combination ketamine-xylazine. Ketamine, a "dissociative anesthetic", suppresses the corticothalamic system and concurrently activates areas of the limbic system;<sup>8,9</sup> however, ketamine alone has been shown to give inadequate analgesia and muscle relaxation.<sup>5,10</sup> Xylazine is a sedative and analgesic with good muscle relaxant properties. The sedative and analgesic properties result from its central nervous system properties, while the muscle relaxation is due to inhibition of intraneural impulse transmission



in the central nervous system.<sup>11</sup> The combination of ketamine and xylazine has been reported to produce good analgesia, anesthesia and muscle relaxation in rabbits and rats.<sup>5,6</sup>

The ketamine-xylazine combination did not decrease the induction time; however, it did prolong the sleep time when compared with ketamine alone. In contrast, an earlier study revealed that the combination of ketamine and acepromazine caused no significant difference in either induction time or sleep time.<sup>7</sup>

Heart rate was decreased in baboons anesthetized with ketamine-xylazine compared with ketamine alone. Ketamine given alone has been previously reported to depress heart rate when compared to measurements with physical restraint in rhesus monkeys.<sup>8</sup> Another recent study found that excitement with physical restraint increased the pulse rate of non-human primates and this could account for the relative decrease when comparing physically restrained and anesthetized non-human primates.<sup>12</sup> An earlier study in man revealed that ketamine alone increased the blood pressure and heart rate.<sup>13</sup>

Muscle hypertonicity, characteristic of anesthesia with ketamine alone, was eliminated with the combination of ketamine-xylazine. This finding is in agreement with earlier findings in cats and rabbits.<sup>2,5</sup> Good muscle relaxation found with ketamine-xylazine is a definite asset permitting good abdominal palpation and ease of surgical manipulations. Another advantage of the ketamine-xylazine combination is the fact that this combination permits passage of an endotracheal tube in contrast with persistence of the laryngeal reflex found with either ketamine alone or the combination of ketamine-acepromazine.<sup>7</sup>

This study revealed that the combination ketamine-xylazine in the baboon produced increased sleep time, decreased heart rate, provided good muscle relaxation, prevented voluntary muscle movement and permitted passage of an endotracheal

tube. Further studies should investigate more physiological measurements, blood gas analyses and hematological effects associated with this anesthetic combination.

#### REFERENCES

1. Beck, C. C. and Dresner, A. J.: Vetalar (ketamine HCl) a cataleptoid anesthetic agent for primate species. Vet Med Small Anim Clin 67:1082-1084, 1972.
2. Amend, J. F., Klavano, P. A. and Stone E. C.: Premedication with xylazine to eliminate muscular hypertonicity in cats during ketamine anesthesia. Vet Med Small Anim Clin 67:1305-1307, 1972.
3. Reid, J. S. and Frank, R. J.: Prevention of undesirable side effects of ketamine anesthesia. J Am Anim Hosp Assoc 8:115, 1972.
4. Prince, M. D., White, G. L. and Holmes, D. D.: Ketamine vs. ketamine-xylazine anesthesia in guinea pigs and rabbits. AALAS Publication 77-9:98, 1977.
5. White, G. L. and Holmes, D. D.: A comparison of ketamine and ketamine-xylazine for effective surgical anesthesia in the rabbit. Lab Anim Sci 26: 804-806, 1976.
6. Van Pelt, L. F.: Ketamine and xylazine for surgical anesthesia in rats. JAVMA 171:842-844, 1977.
7. Connolly, R. and Quimby, F. W.: Acepromazine-ketamine anesthesia in the rhesus monkey (Macaca mulatta). Lab Anim Sci 28:72-74, 1978.
8. Ochsner, A. J.: Cardiovascular and respiratory responses to ketamine hydrochloride in the rhesus monkey (Macaca mulatta). Lab Anim Sci 27:69-71, 1977.
9. Corssen, G., Miyasaka, M. and Domino, E. F.: Changing concepts in pain control during surgery. Dissociative anesthesia with CI-581. A Progress Report. Anesth & Analg 47:746-748, 1968.
10. Green, C. J.: Neuroleptanalgesia drug combination in the anesthetic management of small laboratory animals. Lab Anim 9:161-178, 1975.

11. Shmidl, J. A.: Experimental use of rompum in the exotic species. J Zool Anim Med 5(4):8-11, 1974.
12. Bush, M., Caster, R., Smeller, J. and Bush, L. M.: Physiologic measures of non-human primates during physical restraint and chemical immobilization. JAVMA 171:866-869, 1977.
13. Vayden, S., Hunt, J., Willis, K. W. and Stephen, C. R.: Cardiovascular and respiratory function with CI-581. Anesth & Analg 47:760-768, 1968.



TABLE I. HEART RATE (Mean  $\pm$ SE)

TIME	+10 MIN	+20 MIN	+30 MIN
Group A*	135 ( $\pm 6$ )	131 ( $\pm 4$ )	131 ( $\pm 3$ )
Ketamine			
P		NS	NS
Group B**	106 ( $\pm 8$ )	96 ( $\pm 6$ )	97 ( $\pm 9$ )
Ketamine-xylozine			
P		.025	.02
P <sub>≠</sub>	.02	.005	.005

\* Group A (N=6) were administered 11 mg/kg ketamine hydrochloride

\*\* Group B (N=6) were administered 11 mg/kg ketamine and .5 mg/kg xylozine

P = Paired comparisons for +20 and +30 minutes compared to +10 minutes

P<sub>≠</sub> = Unpaired comparisons between Groups A and B

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

REPORT DOCUMENTATION PAGE		READ INSTRUCTIONS BEFORE COMPLETING FORM
1. REPORT NUMBER Technical Report No. 133	2. GOVT ACCESSION NO.	3. RECIPIENT'S CATALOG NUMBER
4. TITLE (and Subtitle) A COMPARISON OF KETAMINE AND KETAMINE-XYLAZINE ANESTHESIA IN THE BABOON		5. TYPE OF REPORT & PERIOD COVERED Technical Report
		6. PERFORMING ORG. REPORT NUMBER
7. AUTHOR(s) Gary L. White and John F. Cummings		8. CONTRACT OR GRANT NUMBER(s) N00014-76-C-0229
9. PERFORMING ORGANIZATION NAME AND ADDRESS University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma		10. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS
11. CONTROLLING OFFICE NAME AND ADDRESS Office of Naval Research Arlington, Virginia		12. REPORT DATE 12 February 1979
		13. NUMBER OF PAGES 8
14. MONITORING AGENCY NAME & ADDRESS (if different from Controlling Office)		15. SECURITY CLASS. (of this report)
		15a. DECLASSIFICATION/DOWNGRADING SCHEDULE
16. DISTRIBUTION STATEMENT (of this Report) Distribution of this report is unlimited		
17. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Report)		
18. SUPPLEMENTARY NOTES		
19. KEY WORDS (Continue on reverse side if necessary and identify by block number) baboon ketamine ketamine-xylazine anesthesia		
20. ABSTRACT (Continue on reverse side if necessary and identify by block number) Ketamine alone and ketamine-xylazine were studied in the baboon to compare their induction time, sleep times, heart rates, and muscle relaxant properties. The combination of ketamine and xylazine produced an extended sleep time, decreased heart rate, and good muscle relaxation when compared with ketamine alone.		

DD FORM 1473  
1 JAN 73

EDITION OF 1 NOV 65 IS OBSOLETE  
S/N 0102-014-6601

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

OFFICE OF NAVAL RESEARCH  
BIOLOGICAL SCIENCES DIVISION  
BIOPHYSICS PROGRAM, Code 444  
DISTRIBUTION LIST FOR TECHNICAL, ANNUAL AND FINAL REPORTS

Number of Copies

- (12) Administrator, Defense Documentation Center  
Cameron Station  
Alexandria, Virginia 22314
- (6) Director, Naval Research Laboratory  
Attention: Technical Information Division  
Code 2627  
Washington, D. C. 20375
- (3) Office of Naval Research  
Biophysics Program  
Code 444  
Arlington, Virginia 22217
- (1) Commanding Officer  
Naval Medical Research and Development Command  
National Naval Medical Center  
Bethesda, Maryland 20014
- (1) Chief, Bureau of Medicine and Surgery  
Department of the Navy  
Washington, D. C. 20375
- (2) Technical Reference Library  
Naval Medical Research Institute  
National Naval Medical Center  
Bethesda, Maryland 20014
- (1) Office of Naval Research Branch Office  
495 Summer Street  
Boston, Massachusetts 02210
- (1) Office of Naval Research Branch Office  
536 South Clark Street  
Chicago, Illinois 60605

Enclosure (3)



- (1) Office of Naval Research Branch Office  
1030 East Green Street  
Pasadena, California 91106
- (1) Commanding Officer  
Naval Medical Research Unit No. 2  
Box 14  
APO San Francisco 96263
- (1) Commanding Officer  
Naval Medical Research Unit No. 3  
FPO New York 09527
- (1) Officer in Charge  
Submarine Medical Research Laboratory  
Naval Submarine Base, New London  
Groton, Connecticut 06342
- (1) Scientific Library  
Naval Medical Field Research Laboratory  
Camp Lejeune, North Carolina 28542
- (1) Scientific Library  
Naval Aerospace Medical Research Institute  
Naval Aerospace Medical Center  
Pensacola, Florida 32512
- (1) Commanding Officer  
Naval Air Development Center  
Attn: Aerospace Medical Research Department  
Warminster, Pennsylvania 18974
- (1) DIRECTOR  
Naval Biosciences Laboratory  
Building 844  
Naval Supply Center  
Oakland, California 94625
- (1) Commander, Army Research Office  
P. O. Box 12211  
Research Triangle Park  
North Carolina 27709
- (1) DIRECTOR OF LIFE SCIENCES  
Air Force Office of Scientific Research  
Bolling Air Force Base  
Washington, D. C. 20332



- (1) Commanding General  
Army Medical Research and Development Command  
Forrestal Building  
Washington, D. C. 20314
- (1) Department of the Army  
U. S. Army Science and  
Technology Center - Far East  
APO San Francisco 96328
- (1) Assistant Chief for Technology  
Office of Naval Research, Code 200  
800 N. Quincy Street  
Arlington, Virginia 22217

**The University of Oklahoma Health Sciences Center**

This institution, in compliance with Title VI of the Civil Rights Act of 1964 and Title IX of the Education Amendments of 1972, does not discriminate on the basis of race, color, national origin, or sex in any of its policies, practices or procedures. This includes but is not limited to admissions, employment, financial aid, and educational services.

This institution, in compliance with the Rehabilitation Act of 1973 and the Vietnam Era Veterans Readjustment Assistance Act of 1974, does not discriminate in employment on the basis of physical or mental handicap or service-related disability unless the handicap or service-related disability precludes successful performance as determined by established minimum bona fide occupational qualifications for employment; moreover, this institution does not discriminate in any of its employment policies, practices, or procedures on the basis of satisfactory military service during the Vietnam era.